Elisa Herraez, Elisa Lozano, Rocio I.R. Macias, Javier Vaquero, Luis Bujanda, Jesus M. Banales, Jose J.G. Marin, Oscar Briz – 26 March 2013 – Reduced drug uptake is an important mechanism of chemoresistance. Down‐regulation of SLC22A1 encoding the organic cation transporter‐1 (OCT1) may affect the response of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CGC) to sorafenib, a cationic drug. Here we investigated whether SLC22A1 variants may contribute to sorafenib chemoresistance.

Jens U. Marquardt, Kerstin Fischer, Katharina Baus, Anubha Kashyap, Shengyun Ma, Markus Krupp, Matthias Linke, Andreas Teufel, Ulrich Zechner, Dennis Strand, Snorri S. Thorgeirsson, Peter R. Galle, Susanne Strand – 23 March 2013 – Sirtuin 6 (SIRT6) is a member of the sirtuin family of NAD+–dependent deacetylases. Genetic deletion of Sirt6 in mice results in a severe degenerative phenotype with impaired liver function and premature death. The role of SIRT6 in development and progression of hepatocellular carcinoma is currently unknown.

Frederick J. Suchy – 23 March 2013

Cliff Rowe, Dave T. Gerrard, Roz Jenkins, Andrew Berry, Kesta Durkin, Lars Sundstrom, Chris E. Goldring, B. Kevin Park, Neil R. Kitteringham, Karen Piper Hanley, Neil A. Hanley – 23 March 2013 – Failure to predict hepatotoxic drugs in preclinical testing makes it imperative to develop better liver models with a stable phenotype in culture. Stem cell‐derived models offer promise, with differentiated hepatocyte‐like cells currently considered to be “fetal‐like” in their maturity.

Laura Elisa Buitrago‐Molina, Silke Marhenke, Thomas Longerich, Amar Deep Sharma, Aristeidis E. Boukouris, Robert Geffers, Bruno Guigas, Michael P. Manns, Arndt Vogel – 23 March 2013 – Hepatocellular carcinoma (HCC) frequently arises in the context of chronic injury that promotes DNA damage and chromosomal aberrations. The cyclin‐dependent kinase inhibitor p21 is an important transcriptional target of several tumor suppressors, which promotes cell cycle arrest in response to many stimuli.

Matthias Evert, Frank Dombrowski, Biao Fan, Silvia Ribback, Xin Chen, Diego F. Calvisi – 23 March 2013

Petia Jeliazkova, Simone Jörs, Jens T. Siveke, Fabian Geisler – 23 March 2013

Yu‐Shu Cheng, Ping‐Yi Lin, Kuo‐Hua Lin, Chih‐Jan Ko, Chia‐Cheng Lin, Yao‐Li Chen – 22 March 2013

Eytan Mor, Eviatar Nesher, Ziv Ben‐Ari, Irit Weissman, Ezra Shaharabani, Sigal Eizner, Evegny Solomonov, Ruth Rahamimov, Marius Braun – 22 March 2013 – Using living donor organs for sequential liver and kidney transplantation (SeqLKT) in patients with primary hyperoxaluria type 1 (PH1) has emerged as a viable approach. Taking both organs from a single donor, however, is rare. There are 8 reported cases of SeqLKT in the literature, and in all but 1 case, children were the recipients. We present our experience with SeqLKT in 2 young adults with PH1.

Humberto E. Bohorquez, Ari J. Cohen, Nigel Girgrah, David S. Bruce, Ian C. Carmody, Shoba Joshi, Trevor W. Reichman, George Therapondos, Andrew L. Mason, George E. Loss – 22 March 2013 – The use of livers from hepatitis B surface antigen–negative (HBsAg−)/hepatitis B core antibody–positive (HBcAb+) donors in liver transplantation (LT) for HBsAg−/HBcAb− recipients is still controversial because of a lack of standard antiviral prophylaxis and long‐term follow‐up. We present our 13‐year experience with the use of HBcAb+ donor livers in HBcAb− recipients.